# Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients

> **NCT02246686** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 3 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** STW5-II (Iberogast N, BAY98-7410)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02246686
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-02
- **Final completion:** 2016-04
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2016-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246686, "Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02246686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*